Stockreport

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome, Inc.  (IMNM) 
PDF Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025IM-1021 and IM-3050 IND filings expected in first quarter of 2025Current cash expected [Read more]